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ABSTRACT
OBJECTIVE: The objective of this selective EBM review is to determine whether or not “Is
tranexamic acid effective in reducing postoperative blood loss in adult patients with lumbar
degenerative disease who are undergoing posterior lumbar spinal fusion surgery?”
STUDY DESIGN: A review of two double-blinded randomized controlled trials (RCT) and one
RCT.
DATA SOURCES: All articles were peer-reviewed and published in English between 20172020. They were found through PubMed and chosen based on ability to answer the objective.
OUTCOMES MEASURED: The outcome measured in all articles was the objective amount of
blood loss in mL contained in drainage output through postoperative day two. Xu et al. 2020 and
Xu et al. 2017 calculated the pure blood contained in the postoperative drainage, while Kim et al.
considered all fluid in the postoperative drainage to represent blood loss.
RESULTS: Xu et al. 2020 found a statistically significant difference (p-value <0.05) between
the tranexamic acid (TXA) group, whose mean blood loss represented as mean  standard
deviation was 55.0 23, and the placebo group, whose blood loss was reported as 114.5 45.9.
There was a mean difference of 59.5 between the groups. The study performed by Xu et al. 2017
found that average blood loss was 39.9 28.5 in the TXA group, and 160.2 82.8 in the placebo
group, with a statistically significant p-value of 0.001. The mean difference between groups was
120.3. Kim et al. reported a mean 24-hour postoperative blood loss of 384 33 in the TXA
group, and 541 28 in the placebo group, with a p-value of 0.04 and a mean difference of 157.
Blood loss upon drain removal in the TXA group was 149 18 and was 274 50 in the placebo
group, with a p-value of 0.02 and a mean difference of 125.
CONCLUSION: All studies in this review found that use of TXA in posterior lumbar interbody
fusion (PLIF) was effective in decreasing postoperative blood loss in patients with severe lumbar
degenerative disease. Future studies could focus on optimal dosing and route of TXA
administration.
KEY WORDS: tranexamic acid, spinal surgery
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INTRODUCTION
Degenerative lumbar spine disease, including spinal stenosis, disc herniation, and
spondylolisthesis, is a leading cause of acute and chronic low back pain (LBP), which has a
lifetime prevalence of 60-80% in the United States.1,2 LBP is the second most common reason
for healthcare visits behind upper respiratory infections, and in 2013, it accounted for 62 million
inpatient and outpatient visits.3 Spinal stenosis is narrowing of the spinal canal, disc herniation is
bulging of the nucleus pulposus through the annulus fibrosis, and spondylolisthesis describes a
misalignment resulting from the slippage of a vertebral body anteriorly. Degenerative spine
disease affects 27.3% of the US1 and 3.63% of the world each year, especially obese, older
females.4 According to the National Commission on Certification of Physician Assistants’
(NCCPA) 2020 annual report, 18.1% of physician assistants (PAs) worked in primary care and
10.9% worked in orthopedic surgery, making family medicine and surgical subspecialties the top
specialties with the highest percentage of PAs.5 Therefore, it is important that PAs be aware of
the management and complications associated with degenerative spine disease.
Conservative measures including lifestyle changes, non-steroidal anti-inflammatories
(NSAIDs), corticosteroid injections, and physical therapy are initially implemented to manage
degenerative disease, but spinal fusion is the gold standard treatment for severe instability failing
these measures. There has been a rate increase of 73% from 2004 to 2015 for adults 65 and older
requiring lumbar fusions for degenerative spinal disease.6 Surgical interventions, such as
laminectomy, foraminotomy, and fusion, depend on the specific condition and how advanced it
is. Posterior lumbar interbody fusion (PLIF) is common in all types of unstable degenerative
disease. In 2014, 69 030 PLIFs were performed in the US.2 However, spinal fusions are among
the most common surgeries associated with significant intraoperative, postoperative and hidden
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blood loss.2 An average loss of 1000 mL can occur, leading to delayed wound healing, anemia,
increased morbidity and mortality, including complications such as pulmonary embolisms, deep
venous thromboses (DVTs), and myocardial infarctions, and longer hospital stays, which can all
result in higher medical expenses.7,8 A PLIF procedure costs a patient on average $29 948,2 and
in 2015, inpatient spinal fusions cost hospitals 24.3 billion dollars.6 To treat blood loss,
allogeneic red cell, platelet, or clotting factor transfusions are required.

The incidence of blood transfusions in the US following fusions is 30% for all spinal levels
and 11% specifically for lumbar fusions.9 The average cost of a transfusion following PLIF is
$1980 per patient.10 Transfusion administration is dependent on age, gender, and comorbidities
of the patient, as well as surgical approach (i.e. posterior, anterior, lateral) and operative time.9 In
order to prevent surgical blood loss, positioning to reduce intra-abdominal pressure, hypotensive
anesthesia, Cell Saver, topical hemostatic agents and antifibrinolytics are all methods used in
practice. It is unknown, however, the most efficacious, cost-effective, and practical intervention
to minimize surgical blood loss and subsequent complications and transfusions.

Tranexamic acid (TXA) is a synthetic antifibrinolytic that works by blocking plasminogen
activation and therefore preventing fibrinolysis. It is commonly used in orthopedic surgeries such
as knee and hip arthroplasties to prevent substantial blood loss.7 Out of all methods to prevent
blood loss during interbody fusions, some studies suggest that antifibrinolytics are highly
effective due to their mechanism and onset of action. 10 However, questions persist about the
efficacy regarding TXA specifically and if the cost of using TXA is less than that from
complications and transfusions following surgery.10 This paper evaluates three randomized
controlled trials (RCTs) that assess the efficacy of TXA in reducing blood loss in PLIFs.
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OBJECTIVE
The objective of this selective EBM review is to determine whether or not “Is tranexamic acid
effective in reducing postoperative blood loss in adult patients with lumbar degenerative disease
who are undergoing posterior lumbar spinal fusion surgery?”

METHODS

The population in this review included adults with degenerative lumbar disease requiring
spinal surgery. Key words of “tranexamic acid” and “spinal surgery” were used to search
PubMed for articles that were selected based on their inclusion of patient-oriented outcomes that
matter (POEMs), publication date, outcome measurement, and ability to answer the objective.
All articles were published in peer-reviewed journals in the English language and consisted of
blinded, randomized controlled trials (RCTs) that compared the intervention of TXA to placebo,
which was represented by normal saline or gelatin sponge. Table 1 represents the demographics
of the chosen studies.

Inclusion criteria included full text RCTs published after 2017 involving adults aged 19 and
older in clinical trials. Articles published before 2017 that involved patients under the age of 19
and were not primary sources or peer reviewed were excluded. P-values, mean, and standard
deviation were used to evaluate the statistical significance of the data.

OUTCOMES MEASURED
Postoperative blood loss was measured by adding up the total mL amount of drainage output
after surgery. Xu et al. 2020 and Xu et al. 2017 obtained the hematocrit (Hct) and hemoglobin
(Hb) from a complete blood count (CBC) taken from drainage samples on postoperative days
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one and two from a deep fascial drain placed before surgical closure. They calculated the amount
of pure blood in the drainage output with the following formula: volume of drainage x (Hct of
drainage/ average Hct of patient).7,11 Kim et al. measured postoperative blood loss by adding up
the mL amount of fluid in the drainage output 24 hours after surgery and upon drain removal.8
Table 1.-Demographics & Characteristics of Included Studies
Study

Type

Age
(yrs)
3463

Inclusion criteria

Exclusion criteria

RCT

#
Pts
60

Xu7
(2020)

W/
D
0

Spondylolisthesis;
spondylolysis,
severe spinal
instability; large
disc herniation

Xu11
(2017)

RCT

120

4070

Spinal
degenerative
disease- stenosis,
disc diseases,
spondylolisthesis/
spondylolysis

Kim8
(2017)

Double
blind
RCT

72

5272

Symptomatic
lumbar spinal
stenosis with
spondylolisthesis
who failed
physiotherapy

Coagulation defects;
anemia;
cardiovascular
disease (CVD); 2+
surgical levels; use of
antiplatelets/
anticoagulants in last
month; cell saver
salvage system use
during surgery
Osteoporosis;
0
anemia; renal failure;
CVD; abnormal
coagulation function;
antiplatelet/anticoagu
lant use in past
month; history of
VTE
Previous spinal
0
surgery; coagulation/
bleeding issues;
renal/ hepatic disease;
CI to antifibrinolytics

Intervention
s
Surgical field
immersed in
TXA vs
surgical field
immersed in
normal saline
(placebo)

Topical TXA
vs gelatin
sponge
(placebo)

TXA (10
mg/kg in 100
mL 0.9% NS
with infusion
rate 2
mg/kg/h until
5 hours after
surgery) vs
0.9% normal
saline 100mL
(placebo)
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RESULTS
Xu et al. 2020 conducted an RCT from Nov. 2013 to April 2017 at Peking Union Medical
College Hospital in Beijing, China involving 60 patients with lumbar degenerative disease with
the inclusion and exclusion criteria in Table 1 in order to determine how TXA affected blood
loss in PLIF with focus on hidden blood loss.7 Patients were randomized into placebo and TXA
groups, 30 in each, using a simple equal probability scheme.7 They were similar in height,
weight, body mass index (BMI), preoperative Hb levels, and spinal fusion level.7 The mean age
of patients was 50.1 14.3 years, the female: male ratio was 33:27, and average operative time
was 138.8 22.9 min.7 All procedures were performed by one surgeon who, in addition to the
researchers, were blinded to the intervention. The article did not report if patients were blinded.
In the TXA group, a solution of 1g TXA in 100 mL saline was applied to the surgical field for
five minutes at the conclusion of the procedure.7 The placebo group received normal saline in the
same volume under the same conditions. Postoperative blood loss was measured as the volume
of calculated pure blood in the drainage. Drains were removed once <50 mL of output over a 24hour period was produced. No patients were withdrawn from the study, and no adverse effects
such as thromboembolic incidents, hematomas, or infections were reported in either group.7
The total blood in the postoperative drainage measured in mL, reported as mean  standard
deviation (SD), was 114.5 45.9 in the control group and 55.0 23 in the TXA group with a
statistically significant p-value of <0.05, indicating that the TXA group had a smaller amount of
blood loss compared to the control group.7 The mean difference between groups was calculated
to be 59.5. The TXA group had a smaller drainage volume and less pure blood loss on postop
day one than the control group.7 Both groups had similar drainage volume on postop day two.
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Table 2. Comparison of Postoperative Blood Loss Between TXA and Placebo Group in
Study by Xu et al. 20207
Mean Difference
P-value
Mean  SD
Between Groups
(Calculated)
TXA Group
55.0  23
59.5
<0.05
Placebo Group
114.5  45.9

Xu et al. 2017 conducted an RCT from Nov. 2013 to Oct. 2016 at Peking Union Medical
Hospital involving 120 patients with spinal degenerative disease with the inclusion and exclusion
criteria in Table 1 in order to determine how effective topical TXA, gelatin sponge, and collagen
sponge were at reducing blood loss in spinal fusions.11 A simple equal probability randomization
scheme was used to allocate patients: 40 in the topical TXA group, 40 in the gelatin sponge, and
40 in the collagen sponge group.11 For this review, only the results of the TXA and gelatin
sponge, or placebo, group were evaluated. The sex, age, BMI, Hb before surgery, surgical level
and total operative time were reported as similar between all groups, but had a reported p-value
of >0.05.11 The same group of surgeons performed all the procedures, which involved a total
laminectomy with pedicle screws for the fusion and discectomy if herniation was present. The
article does not mention if participants, surgeons, or researchers were blinded.
For the TXA group, 1g TXA in 100 mL saline solution submerged the surgical field five
minutes after fusion was complete and then was removed via aspiration before wound closure.11
The placebo group received a gelatin sponge approximated to the size of the dura that was
exposed. Postoperative blood loss was measured in the same way as Xu et al. 20207 by
calculating the pure blood content in the drainage volume. When <50 mL of output was obtained
over a 24-hour period, drains were removed. No patients withdrew from the study, and no
complications such as thromboembolic events, hematomas, or infections occurred in any group. 11
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The data, represented as mean  SD, showed that the mL amount of blood in the drainage was
160.2 82.8 in the gelatin sponge group and 39.9 28.5 in the TXA group with a statistically
significant p-value = 0.001, indicating that the TXA group experienced a smaller amount of
blood loss compared to the gelatin sponge group.11 The mean difference between groups was
calculated to be 120.3. On postoperative day one, the TXA group had the least amount of total
drainage and pure blood volume when compared to the gelatin sponge group.11 There were no
significant differences in drainage volume and blood content on postoperative day two.
Table 3. Comparison of Postoperative Blood Loss Between TXA and Placebo Group in
Study by Xu et al. 201711
Mean Difference
P-value
Mean  SD
Between Groups
(Calculated)
TXA Group
39.9  28.5
120.3
0.001
Gelatin Sponge
160.2  82.8
Group
Kim et al. performed an RCT with 72 patients, 37 women and 35 men, with symptomatic
lumbar degenerative disease who met the inclusion and exclusion criteria in Table 1 in order to
determine the overall effectiveness of TXA in reducing blood loss during PLIF when
administered five minutes before surgery.8 The study was performed from Jan. 2014 to April
2015 at a single institution, the location of which was not disclosed. Because researchers were
also interested in the optimal dosage of TXA, patients were randomized using a computer
program into a placebo group, a high dose TXA group, and a low dose TXA group.8 For this
review, the high dose TXA group was compared with the placebo group. The one surgeon who
performed all the procedures, the patients, and the researchers were blinded; only the anesthetist
was aware on the day of surgery due to safety concerns.8 The average age of patients was 63.3 
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7.6 years with an average BMI of 25.3 3.0.8 Fusion levels ranged from L3-S1, and the duration
of surgery between groups was said to be similar, but had a reported p-value of 0.91.8
The intervention for the TXA group was a 10 mg/kg TXA bolus in 100 mL normal 0.9%
saline given five minutes before the initial incision with a 2 mg/kg/h infusion continued for five
hours after surgical completion.8 Those in the placebo group were given 100 mL normal 0.9%
saline bolus with a crystalloid infusion to follow. Postoperative blood loss was measured by
adding up the drainage output 24-hours after surgery and upon drain removal.8 Unlike the
aforementioned studies, the output potentially included other postoperative fluids in addition to
pure blood. Once there was <50 mL of output after a 24-hour period, the drain was removed.
There were no withdrawals from the study, and the only complications reported were two cases
of DVTs in the placebo group after postoperative week one with none in the TXA group.8
The 24-hour postoperative blood loss in mL, represented as mean  SD, was 541 28 for the
placebo group, and 384 33 in the TXA group with a statistically significant p-value of 0.04 and
a mean difference calculation of 157.8 The mL of blood loss measured during drain removal was
274 50 in the control group, and 149 18 in the TXA group with a statistically significant pvalue of 0.02 and a mean difference calculation of 125.8 Therefore, this suggested that use of
TXA reduced the amount of 24-hour postoperative blood loss and blood loss upon drain removal
when compared to the placebo group.
Table 4. Comparison of 24-Hour Postoperative Blood Loss Between TXA and Placebo
Group in Study by Kim et al. 20178
24-Hour
Mean Difference
ANOVA
Postoperative Blood
Between Groups
P-value
Loss
(Calculated)
Mean  SD
High Dose TXA
384  33
Group
157
0.04
Placebo Group
541  28
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Table 5. Comparison of Postoperative Blood Loss Upon Drain Removal Between TXA and
Placebo Group in Study by Kim et al. 20178
Drain Removal
Mean Difference
P-value
Blood Loss
Between Groups
(Calculated)
Mean  SD
High Dose TXA
149  18
Group
125
0.02
Placebo Group
274  50
DISCUSSION
Significant blood loss from spinal fusion is a common and problematic complication that
leads to increased transfusion rates, longer hospital stays, and higher medical expenses. TXA, an
antifibrinolytic approved by the FDA in December 1986 that reversibly binds plasminogen to
prevent it from binding fibrin and inhibiting plasmin, is suggested to be an effective therapy for
blood loss prevention. Its current indications are for heavy menstrual bleeding and extraction of
teeth in those with factor deficiencies.12 It has an off-label use for hemoptysis, dental procedures,
intracranial hemorrhage due to thrombolytics or traumatic brain injury, prevention and treatment
of postpartum hemorrhage, and prevention of blood loss in cardiac, orthopedic, and spinal
surgeries.12 Less than 5% of the drug is metabolized, resulting in excretion through urine in
mainly its original form. It has a relatively good safety profile with minor adverse effects
including abdominal pain, nausea, vomiting, diarrhea, headache, backache, dizziness, visual
defects, hypersensitivity reactions, and is relatively cheap, with a cost of $0.25- $8.68 per mL of
a 1000mg/ 100mL solution in the US.12 There is, however, risk for seizures, retinal artery and
vein occlusions, and thromboembolic disease and is contraindicated in those with active or
history of thromboembolic disease, who use hormonal contraception, who are pregnant, or who
have a history of TXA hypersensitivity.12 It may lead to fatal neurotoxic events if administered
via epidural or spinal route during anesthesia, but has no reported black box warnings.12
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All three RCTs had similar intervention and control groups and found TXA to be effective in
reducing postoperative blood loss in PLIF, indicated by significant p-values. Because of the drug
profile of TXA, the exclusion criteria set by all three studies allowed comprehensive and
appropriate investigation of TXA in a safe manner. To note, Xu et al. 20207 did not mention if
patients were blinded, and Xu et al. 201711 did not report blinding in anyone involved in the trial.
However, because objective measurements of volume in mL were utilized, and no subjective
data was measured, blinding did not obscure the results in these studies enough to render them
invalid. A limitation to the study by Kim et al. was that pure blood in drainage output was not
calculated so that blood loss in this study may not be as accurate as blood loss in the other two
studies. Other limitations common to all studies include lack of intention-to-treat analysis, small
sample size, and utilization of a single clinical site. Because TXA was administered by
healthcare personnel in these studies, patient compliance did not affect the validity of results.

To display the implications of blood loss, Xu et al. 2020 reported that twelve patients in the
control group and five patients in the TXA group required blood transfusions following surgery.7
In the study by Xu et al. 2017 twelve patients in the gelatin sponge group compared to three in
the TXA group required transfusions.11 A number needed to treat (NNT) of five was calculated
from each set of data, indicating that a minimum of five people need to be treated with TXA in
order to prevent one blood transfusion. In both studies, transfusions were required if Hb was
<8g/dL or <10 g/dL and the patient was symptomatic.7,11 Additionally, Xu et al. 2020 found that
patients in the control group experienced an average of 6.9 days in the hospital, while those in
the TXA group experienced 5.1 days.7 Xu et al. 2017 reported that on average, patients in the
TXA group experienced 6.13 days in the hospital while patients in the gelatin sponge group
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experienced 7.82 days.11 The transfusions number and average hospitalization lengths comparing
the gelatin sponge to the TXA group had significant p-values of 0.001 in Xu et al. 2017.11

CONCLUSION

This selective EBM review found conclusive data in all three RCTs that suggest the use of
TXA in PLIF does decrease the amount of postoperative blood loss in patients with severe
lumbar degenerative disease. All three studies were similar in demographics and methodology,
had a relatively large treatment effect with statistically significant p-values, and reported no
adverse effects with use of TXA, suggesting it to be a safe intervention for blood loss and
subsequent transfusion prevention in certain populations. Future studies should be performed
with a larger number of participants across a wider variety of institutions that also include adult
patients younger than 40 years of age. Because this review focused on postoperative blood loss
in single-level PLIFs alone, it would be beneficial to explore use of TXA in multi-level fusions
from different surgical approaches and how it may affect intraoperative blood loss, while also
including main outcome measurements of post-surgical complications and transfusions rates.

Currently, there are many clinical trials exploring the use of TXA for blood loss prevention in
spinal surgery. To note, a trial held by Rush University Medical Center in Chicago, IL is
investigating the most efficacious route of TXA delivery (topical, oral, or intravenous), as well
as the optimal dosing of TXA in spinal surgery.13 Another significant study estimated to be
completed in January 2021 is being performed by Albany Medical College in New York
investigating the effect of TXA on blood loss in spinal procedures with and without fusion.14
Data from current trials and ongoing research into TXA use will help determine the potential role
that TXA plays in the field of spinal and even other surgical specialties.
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